Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study
Articolo
Data di Pubblicazione:
2014
Abstract:
Little is known about mode of death after acute heart failure (AHF) hospitalization. In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
cause of death; heart failure; relaxin; sudden cardiac death; Acute Disease; Aged; Cause of Death; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Injections, Intravenous; Male; Prospective Studies; Recombinant Proteins; Relaxin; Survival Rate; Treatment Outcome
Elenco autori:
Felker, G. Michael; Teerlink, John R; Butler, Javed; Hernandez, Adrian F; Miller, Alan B; Cotter, Gad; Davison, Beth A; Filippatos, Gerasimos; Greenberg, Barry H; Ponikowski, Piotr; Voors, Adriaan A; Hua, Tsushung A; Severin, Thomas M; Unemori, Elaine; Metra, Marco
Link alla scheda completa:
Pubblicato in: